Olanzapine
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
Olanzapine: From Antipsychotic Therapy to Agoraphobia
One-Sentence Summary
Olanzapine is a well-established second-generation antipsychotic, though this evidence pack does not capture its UK licensed indications (data gap). The TxGNN model’s strongest evidence-supported signal points to Agoraphobia (typically evaluated in the context of treatment-resistant panic disorder), with 0 clinical trials but 7 supporting publications (mainly reviews, one open-label trial, and case reports) currently underpinning this direction.
Note on candidate selection: This evidence pack contains three TxGNN-ranked predictions. The highest-scoring candidate by raw model score (benign paroxysmal torticollis of infancy) has no supporting literature, no clinical trials, and no mechanistic rationale — the evidence pack itself flags this as reflecting graph topology similarity only, with unknown safety in infants. It has therefore not been selected as the headline indication. See “Other TxGNN-Ranked Candidates” below for full transparency.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in this evidence pack (data gap). Olanzapine is widely recognised as a second-generation antipsychotic used in schizophrenia and bipolar disorder. |
| Predicted New Indication | Agoraphobia (evidence concentrated in treatment-resistant panic disorder with agoraphobia) |
| TxGNN Prediction Score | 99.47% |
| Evidence Level | L3 |
| UK Market Status | Not marketed (per this evidence pack — see caveat below) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Olanzapine is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the supporting literature within the pack, Olanzapine’s known pharmacology — 5-HT2A and dopamine (D2) antagonism, alongside H1 and M1 activity — is proposed to modulate amygdala–prefrontal anxiety circuitry, which is the rationale cited for its use as an augmentation agent.
The clinical link is not to agoraphobia as a standalone diagnosis, but to treatment-resistant panic disorder with agoraphobia, where Olanzapine has been trialled as an add-on to SSRIs in patients who failed first-line therapy. This is an important distinction: agoraphobia and panic disorder frequently co-occur and are studied together, but they are not identical diagnostic entities, and the evidence base reflects this overlap rather than agoraphobia in isolation.
Mechanistically this is plausible as a second-line augmentation strategy in a narrow, treatment-resistant population, but it is not supported by any randomised controlled trial data, and the largest study identified is a 12-week open-label trial (n=31). This places the signal well short of a robust efficacy claim.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40946318 | 2025 | Review | Psychotherapy and Psychosomatics | Integrative review of pharmacological, psychotherapeutic and neurostimulatory options in treatment-resistant anxiety disorders |
| 26635099 | 2016 | Review | Expert Opinion on Pharmacotherapy | Systematic review of treatment-resistant panic disorder management strategies |
| 16415705 | 2006 | Open-label Trial | Journal of Clinical Psychopharmacology | 12-week, fixed-dose (5mg/day) olanzapine augmentation in 31 SSRI-resistant panic disorder patients (with/without agoraphobia); efficacy and tolerability assessed via Panic Attack and Anticipatory Anxiety Scale |
| 25012437 | 2014 | Cohort | Journal of Affective Disorders | 24-month outcomes study examining impact of comorbid agoraphobia/panic/OCD/SAD/GAD on bipolar I disorder course |
| 10739446 | 2000 | Case Report | American Journal of Psychiatry | Early case report describing olanzapine’s effect on panic attacks |
| 15470803 | 2004 | Case Report | Pharmacopsychiatry | Case of remission from treatment-refractory panic disorder with olanzapine + paroxetine combination |
| 17099612 | 2006 | Case Report | Psychiatria Danubina | Case of panic disorder with agoraphobia comorbid with psychosis, managed via CBT |
Other TxGNN-Ranked Candidates (Not Selected as Headline)
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Notes |
|---|---|---|---|---|---|
| 1 | Benign paroxysmal torticollis of infancy | 99.54% | L5 | Hold | No clinical trials, no literature, no mechanistic plausibility. The pack’s own rationale states there is “no support” — BPTI is linked to CACNA1A/vestibular-migraine mechanisms with no known connection to Olanzapine’s D2/5-HT2A/H1/M1 activity. Safety of antipsychotic use in infants is unevaluated. Not clinically actionable. |
| 3 | Dysthymic disorder | 99.28% | L4 | Hold | Only directly relevant study is in patients with borderline personality disorder and comorbid dysthymia (not primary dysthymic disorder). Remaining literature covers second-generation antipsychotics as a class, or other agents (benzamides, amisulpride) rather than Olanzapine specifically. |
UK Market Information
This evidence pack records Olanzapine as not marketed, with 0 licensed products and no licence entries. This does not align with Olanzapine’s well-established global market presence (e.g., as a generic antipsychotic and under the brand Zyprexa), and should be treated as a data completeness gap in this evidence pack rather than confirmation of actual UK licensing status. MHRA/SmPC records should be independently verified before this report is used for any regulatory or clinical decision.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This evidence pack flags a Blocking data gap (DG001) — UK product label warnings/contraindications and drug–drug interaction data were not available at the time of this report. No safety assessment can be considered complete until this is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: The best-supported candidate (agoraphobia, via treatment-resistant panic disorder) rests on L3 evidence — open-label and case-report data only, with no RCTs — and is further constrained by a Blocking safety data gap (no verified UK warnings, contraindications, or DDI data). The top TxGNN-scored candidate (infantile torticollis) is explicitly unsupported by mechanism or literature and should not be pursued.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain verified UK SmPC/BNF warnings and contraindications
- Resolve DG002 (High): confirm Olanzapine’s mechanism of action from DrugBank or equivalent source
- Verify actual UK/MHRA licensing status (current “not marketed” status appears inconsistent with known market presence)
- Identify controlled trial data (ideally RCT) for olanzapine augmentation specifically in agoraphobia or panic disorder with agoraphobia
- Clarify diagnostic scope: distinguish agoraphobia as a standalone target versus panic disorder with agoraphobia as studied in the literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.